OriCiro Genomics
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
OriCiro Genomics was a Tokyo biotech startup founded in 2018 to commercialize Professor Masayuki Suetsugu's (Rikkyo University) cell-free DNA amplification technology, incubated by the University of Tokyo's UTEC. While conventional DNA synthesis uses living cells like E. coli, OriCiro's platform enabled rapid, cell-free assembly and amplification of large DNA - including sequences impossible to amplify by existing methods - sold as reagent kits, co-development, and technology licensing for plasmid DNA manufacturing in synthetic biology and advanced therapies.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Founded
OriCiro Genomics was founded in Tokyo in 2018, led by president Seiji Hirasaki and co-founder/CSO Masayuki Suetsugu, with UTEC driving the commercialization of the cell-free DNA technology.
- Acquired
On January 31, 2023 Moderna acquired OriCiro Genomics for $85 million - its first acquisition since 2010 - gaining cell-free plasmid DNA synthesis tools to accelerate mRNA vaccine manufacturing.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.